Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27395756 | 0.92 | MEN1 (0.61) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL3505843 | 0.86 | ALDH1A1 (0.70) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL6757032 | 0.86 | ALDH1A1 (0.55) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL12579365 | 0.85 | MEN1 (0.57) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL3509441 | 0.85 | PDE7A (0.68) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL3484361 | 0.84 | MEN1 (0.56) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL3484189 | 0.83 | TDP1 (0.64) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL10789320 | 0.83 | TDP1 (0.81) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL12579354 | 0.83 | ALDH1A1 (0.55) | MEN1KMT2AGAAPKMALDH1A1 | |
| SCHEMBL31504041 | 0.82 | POLB (0.69) | MEN1KMT2APKMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-1987037-A2 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | MEN1 916/4885KMT2A 1305/4885GAA 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.